Sartorius Stedim Biotech (DIM) AI Stock Analysis

• Market Cap: €17.23B
• Dividend Yield: 0.39%
• Average Volume (3M): 73.64K
• Price to Earnings (P/E): 76.5
• Beta (1Y): 1.41
• Revenue Growth: 5.44%
• EPS Growth: 30.04%
• Country: FR
• Employees: 9,961
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.22
• Shares Outstanding: 97,330,410
• 10 Day Avg. Volume: 65,240
• 30 Day Avg. Volume: 73,643
• PEG Ratio: -2.26
• Price to Book (P/B): 4.58
• Price to Sales (P/S): 6.57
• P/FCF Ratio: 38.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €221.44
• Price Target Upside: 25.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9

• Rating: 55 Neutral
• Price Target: €174.00 ▼(-1.69% Downside)

Sartorius Stedim Biotech's overall stock score is primarily influenced by its solid financial performance, despite challenges in growth and cash flow management. The technical analysis indicates bearish momentum, which is a significant risk factor. The high P/E ratio suggests overvaluation, further impacting the stock's attractiveness. The absence of earnings call and corporate events data limits additional insights.

Sartorius Stedim Biotech Business Overview & Revenue Model

Company Description

Sartorius Stedim Biotech (DIM) is a global leader in biopharmaceutical manufacturing and laboratory services, providing innovative solutions to the life sciences sector. The company specializes in the development and production of bioprocessing equipment and consumables, including filtration systems, bioreactors, and automation solutions, aimed at enhancing the efficiency and effectiveness of biopharmaceutical production. Sartorius Stedim Biotech operates in two primary segments: Bioprocess Solutions and Lab Products & Services, focusing on delivering high-quality products that support the development and manufacturing of biologics, vaccines, and cell and gene therapies.

How the Company Makes Money

Sartorius Stedim Biotech generates revenue primarily through the sale of its bioprocessing equipment, consumables, and laboratory products. Key revenue streams include the direct sale of products such as single-use systems, bioreactors, and filtration devices, as well as recurring revenues from consumables associated with these systems. Additionally, the company benefits from service agreements and maintenance contracts that provide ongoing support to clients. Significant partnerships with leading pharmaceutical and biotechnology companies enhance its market reach and increase sales opportunities. The company's focus on innovation and expansion into emerging markets also contributes to its revenue growth.

Sartorius Stedim Biotech Financial Statement Overview

Summary

Sartorius Stedim Biotech presents a solid financial profile with strong revenue growth and margins, complemented by effective cash flow management and a stable balance sheet. While profitability metrics such as net profit margin and return on equity could see improvement, the company's financial health is generally robust.

Income Statement

The income statement shows a stable revenue base with a modest growth rate of 2.8% in the latest TTM compared to the previous annual period. Gross profit margin is strong at 43.9%, indicating effective cost management. However, the net profit margin is relatively low at 7.1%, suggesting potential pressure on net earnings. EBIT and EBITDA margins are healthy at 15.6% and 25.5%, respectively, reflecting robust operating performance.

Balance Sheet

The balance sheet indicates a moderate debt-to-equity ratio of 0.74, which suggests a balanced approach to leverage. Return on equity stands at 5.1%, pointing to room for improvement in generating returns from equity. The equity ratio is reasonable at 47.8%, reflecting a solid equity foundation. Overall, the balance sheet is stable, though the company could enhance its ROE.

Cash Flow

Cash flow analysis reveals a significant 22.8% growth in free cash flow over the previous annual period, highlighting improved cash generation. The operating cash flow to net income ratio is strong at 4.3, indicating effective cash conversion. The free cash flow to net income ratio of 2.9 further underscores efficient cash flow management. Overall, the company demonstrates robust cash flow performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.90B	2.78B	2.78B	3.49B	2.89B	1.91B
Gross Profit	1.29B	1.21B	1.23B	1.83B	1.55B	1.00B
EBITDA	739.90M	670.50M	755.70M	1.35B	811.96M	623.79M
Net Income	225.20M	175.10M	309.70M	876.10M	414.40M	335.93M
Balance Sheet
Total Assets	8.31B	8.26B	7.74B	5.07B	3.95B	3.07B
Cash, Cash Equivalents and Short-Term Investments	745.10M	688.80M	126.10M	133.00M	237.35M	69.61M
Total Debt	2.97B	2.87B	3.68B	1.14B	625.52M	586.78M
Total Liabilities	4.27B	4.23B	5.07B	2.55B	2.22B	1.59B
Stockholders Equity	4.00B	3.99B	2.64B	2.45B	1.66B	1.46B
Cash Flow
Free Cash Flow	496.50M	475.30M	156.10M	181.70M	371.98M	257.69M
Operating Cash Flow	788.10M	815.10M	629.70M	612.30M	695.97M	416.88M
Investing Cash Flow	-292.80M	-340.00M	-2.72B	-957.50M	-465.23M	-621.12M
Financing Cash Flow	-250.10M	84.90M	1.99B	220.70M	-71.71M	234.07M

Sartorius Stedim Biotech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 177.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Neutral. The current price of 177 is above the 20-day moving average (MA) of 174.96, below the 50-day MA of 190.09, and below the 200-day MA of 192.05, indicating a neutral trend. The MACD of -5.08 indicates Negative momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:DIM.

Sartorius Stedim Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	75 Outperform	$99.55B	11.05	8.39%	4.69%	-9.82%	119.10%
IPN	70 Outperform	€8.84B	19.74	10.82%	1.26%	9.57%	-34.30%
BIM	69 Neutral	€14.95B	34.51	10.86%	0.71%	8.31%	21.00%
ERF	64 Neutral	€12.30B	28.82	11.27%	0.89%	6.25%	18.93%
VIRP	63 Neutral	€2.77B	19.05	14.95%	0.44%	12.07%	20.48%
DIM	55 Neutral	€17.23B	76.48	5.71%	0.39%	5.44%	30.04%
Sector *	53 Neutral	€4.18B	12.96	-41.26%	2.54%	14.43%	-26.74%

Sartorius Stedim Biotech Corporate Events

Sartorius Stedim Biotech Releases 2024 Universal Registration Document

Sartorius Stedim Biotech has announced the availability of its 2024 Universal Registration Document, which includes the group’s business development details for 2024 and the 2025 forecast. This document, now accessible on their investor relations page, also contains the consolidated financial statements for the year ended December 31, 2024. The release of this document provides stakeholders with comprehensive insights into the company’s financial and strategic positioning, potentially impacting investor confidence and industry standing.